Provided by Tiger Trade Technology Pte. Ltd.

SAB Biotherapeutics, Inc.

3.57
+0.09002.59%
Volume:2.99K
Turnover:10.57K
Market Cap:250.88M
PE:-4.49
High:3.57
Open:3.49
Low:3.49
Close:3.48
52wk High:6.60
52wk Low:1.53
Shares:70.28M
Float Shares:48.11M
Volume Ratio:0.32
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7944
EPS(LYR):-0.7944
ROE:14.96%
ROA:-28.20%
PB:1.66
PE(LYR):-4.49

Loading ...

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract With SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

THOMSON REUTERS
·
Yesterday

Emergent BioSolutions Inc: Executed Agreement Is Valued at Approximately $50 Mln

THOMSON REUTERS
·
Yesterday

Emergent BioSolutions Inc - Executed Agreement Is Valued at Approximately $50 Mln

THOMSON REUTERS
·
Yesterday

Emergent BioSolutions: Under Terms, Co to Provide End-to-End Development, Manufacturing Services to SAB Bio

THOMSON REUTERS
·
Yesterday

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding (OtherRHHBY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)

TIPRANKS
·
Apr 24

Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst

TIPRANKS
·
Apr 23

SAB BIO says Phase 1 SAB-142 trial preserves C-peptide in adult type 1 diabetes

Reuters
·
Apr 22

SAB Bio Presents Additional Clinical and Mechanistic Data From SAB-142 Phase 1 Trial in Adult Patients With Established Autoimmune Type 1 Diabetes at Ids 2026

THOMSON REUTERS
·
Apr 22

SAB Biotherapeutics says SAFEGUARD trial of SAB-142 in type 1 diabetes enrolls patients

Reuters
·
Apr 15

SAB Biotherapeutics closes USD 85 million follow-on stock offering

Reuters
·
Mar 20

Press Release: SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Dow Jones
·
Mar 20

BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies

Reuters
·
Mar 19

BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist

Reuters
·
Mar 18

SAB Biotherapeutics launches underwritten public offering of common stock and pre-funded warrants

Reuters
·
Mar 18

SAB Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Mar 18

Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC)

TIPRANKS
·
Mar 12

SAB Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 12

Craig-Hallum Sticks to Their Buy Rating for SAB Biotherapeutics (SABS)

TIPRANKS
·
Mar 11

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

TIPRANKS
·
Mar 11

SAB Reports C-Peptide Preservation Signals in Type 1 Diabetes Trial

MT Newswires Live
·
Mar 11